Published on 23 Mar 2023 on Zacks via Yahoo Finance

Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?

Immuneering Corporation IMRX shares ended the last trading session 16.9% higher at $10.24. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 86.8% gain over the past four weeks.

The rise in Immuneering Corporation's stock price is attributable to positive investor sentiments on the company's pipeline development which is focused on developing a universal-RAS therapy targeting cancer indications. The company is evaluating its lead candidate IMM-1-104 in a Phase I/IIa study in patients with advanced solid tumors harboring RAS mutations.

This company is expected to post quarterly loss of $0.54 per share in its upcoming report, which represents a year-over-year change of -10.2%. Revenues are expected to be $0.15 million, down 16.7% from the year-ago quarter.